Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
242 Chapter 19 · Novel Therapies in <strong>Acute</strong> Lymphoblastic Leukemia<br />
with induction and consolidation regimens in CD20positive<br />
ALL has been explored. Thomas et al. reported<br />
their experience with Hyper-CVAD plus rituximab in<br />
patients with Burkitt and Burkitt-like leukemia and<br />
lymphoma [40]. The CR rate among 22 evaluable non-<br />
HIV patients was 95% with no induction deaths occurring<br />
in this group. With a median follow up of<br />
18 months, only two patients relapsed. Historical experience<br />
of hyper-CVAD alone in mature B ALL showed<br />
a CR rate of 81% with 3-year survival rates of between<br />
17% (patients older than 60 years) and 77% (patients<br />
younger than 60 years). Rituximab has also been reported<br />
to induce molecular remissions in the setting<br />
of minimal residual disease in ALL [41].<br />
Alemtuzumab is a humanized monoclonal antibody<br />
recognizing CD52. CD52 expression is highest on T and<br />
B lymphocytes and most frequently found in chronic<br />
lymphoproliferative disorders. Alemtuzumab has established<br />
activity in chronic lymphocytic leukemia, prolymphocytic,<br />
and other T-cell NHL. CD52 is also detected<br />
in 30–50% of ALL blasts. Experience in ALL is<br />
limited. Anecdotal reports do not support its use as single<br />
agent in relapsed and refractory disease [42]. Alemtuzumab<br />
is currently investigated as part of intense induction/consolidation<br />
programs and in combination<br />
with hyper-CVAD in aggressive T-cell malignancies including<br />
T-cell ALL.<br />
CD19 is expressed on a large proportion of ALL<br />
blasts in most patients with B-lineage disease, and several<br />
antibodies targeting CD19 have been developed and<br />
are investigated in clinical trials. The antitumor activity<br />
of CD19 by itself is weak, but can be enhanced by conjugation<br />
with other components. Ricin is a plant toxin<br />
with potent antiribosomal activity in vitro. When conjugated<br />
as blocked ricin to CD19 (anti-B4 blocked ricin),<br />
enhanced cytotoxic activity in lymphoid malignancies<br />
has been demonstrated [43]. In a small study of relapsed<br />
childhood ALL, biologic activity (reduction in blast percentage)<br />
was observed in five of 19 patients, although no<br />
objective responses occurred. The CALGB used anti-B4<br />
blocked ricin in B-lineage ALL after induction of residual<br />
disease [44]. Although antibody administration was<br />
feasible as part of a complex induction and consolidation<br />
regimen, no benefit could be proven with respect<br />
to remission duration or minimal residual disease levels<br />
as assessed by PCR. Experience with other conjugates<br />
(e.g., the tyrosine kinase inhibitor genistein, pokeweed<br />
antiviral protein immunotoxin) suggest antitumor activity<br />
in small studies, but experience remains limited.<br />
19.2.6 Other Agents<br />
19.2.6.1 Pegylated Asparaginase<br />
L-asparaginase has been an important component of<br />
ALL therapy for many decades. Asparaginase depletes<br />
external sources of asparagine, which ALL blasts require<br />
for survival, as they are unable to synthesize asparagine.<br />
However, native asparaginase has been problematic<br />
for two reasons: (1) need for frequent injections;<br />
and (2) immunogenicity that can result in anaphylactic<br />
reactions or development of neutralizing antibodies<br />
with rapid clearance and short plasma half-lives<br />
of asparaginase [45]. To overcome these shortcomings,<br />
E. coli asparaginase has been covalently linked to<br />
mono-methoxy-polyethylene glycol, rendering native<br />
asparaginase less immunogenic and extending its plasma<br />
half-life to up to 6 days (5–9 times longer), enabling<br />
up to biweekly administrations and thus making therapy<br />
more convenient for patients.<br />
When 144 children with ALL relapse were randomized<br />
to receive PEG-asparaginase either weekly or biweekly,<br />
there was, however, a significant difference in<br />
CR rate favoring weekly administration (97 vs. 82%,<br />
p=0.003) [46]. The CR rate was significantly associated<br />
with higher levels of asparaginase, which in turn correlated<br />
to low antibody titers. Except for infectious complications,<br />
other toxicities including hypersensitivity<br />
(4%) were infrequent. A Children’s Cancer Group study<br />
conducted a randomized comparison of native E. coli<br />
asparaginase and PEG asparaginase in children with<br />
newly diagnosed ALL as part of induction and delayed<br />
intensification [47]. The PEG asparaginase group more<br />
rapidly cleared lymphoblasts from early marrow samples<br />
and developed less frequently antibodies, which<br />
were associated with low asparaginase activity in the<br />
native arm. No difference was noted in event-free survival.<br />
A recent study in 28 children with relapsed ALL<br />
confirmed the pharmacokinetic advantages of PEG asparaginase,<br />
which are characterized by high levels of asparaginase<br />
activity in serum and CSF and consequently<br />
effective asparagine depletion [48]. Limited experience<br />
with PEG asparaginase is available in adult ALL patients.<br />
19.2.6.2 Forodesine (BCX-1777)<br />
Purine nucleoside phosphorylase (PNP) catalyzes the<br />
reversible phosphorolytic cleavage of purine ribonu-